Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here’s What Has Happened Since Its Listing

The newly listed clinical-stage biotechnology company, Metsera Inc. (NASDAQ:MTSR) rose 15.01% on Monday as the broader markets declined.

What Happened: While the company reported insider trades over the last month after its listing on Jan. 31, the stock has advanced 7.55% since it started trading on Nasdaq.

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the company saw significant insider purchases on Feb. 3.

According to Benzinga Pro, three insiders acquired a total of $94.22 million worth of Metsera shares at $18 per share. Specifically, Kristina Burow, Managing Director of ARCH …

Full story available on Benzinga.com